Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants of American Society of Anesthesiologists class 1-3~* Participants of age above or equal to the age of 18 years~* Participants who are scheduled to undergo a laparoscopic cholecystectomy or appendectomy under general anesthesia requiring neuromuscular relaxation with rocuronium, and if applicable, maintenance of neuromuscular blockade~* Participants who have given written informed consent~Exclusion Criteria:~* Participants in whom a difficult intubation because of anatomical malformations is expected~* Participants known or suspected to have neuromuscular disorders affecting NMB~* Participants known or suspected to have a significant renal dysfunction~* Participants known or suspected to have a severe hepatic dysfunction~* Participants known or suspected to have (family) history of malignant hyperthermia~* Participants known or suspected to have an allergy to opioids, muscle relaxants or other medication used during general anesthesia~* Participants in whom the use of neostigmine and/or atropine is contraindicated~* Female participants who are pregnant (pregnancy will be excluded for women both from medical history and by a human chorionic gonadotropin (hCG) test within 24h before surgery, except for women who are not of childbearing potential, i.e. at least 2 years menopausal or have undergone tubal ligation or a hysterectomy)~* Female participants who are breast-feeding~* Participants who participated in another clinical trial not pre-approved by the sponsor, within 30 days of entering into trial 19.4.318 (P05699)~* Participants who have already participated in a sugammadex trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): 4.0 mg.kg-1 sugammadex at 1-2 PTC
- Neostigmine (Type: EXPERIMENTAL): 50 µg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2

Based on this trial design, predict the completion outcome and termination type (if applicable).